Premium
Impact of sirolimus‐eluting stents on outcomes of patients treated for acute myocardial infarction by primary angioplasty
Author(s) -
Cheneau Edouard,
Rha SeungWoon,
Kuchulakanti Pramod K.,
Stabile Eugenio,
Kinnaird Timothy,
Torguson Rebecca,
Pichard Augusto D.,
Satler Lowell F.,
Kent Kenneth M.,
Waksman Ron
Publication year - 2005
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.20395
Subject(s) - medicine , angioplasty , myocardial infarction , cardiology , timi , percutaneous coronary intervention , stent , revascularization , primary angioplasty
Sirolimus‐eluting stents (SESs) are currently being used in patients undergoing percutaneous coronary intervention (PCI). SESs have not been evaluated in the treatment of acute myocardial infarction by primary angioplasty. We report our initial experience with SESs implanted during primary angioplasty. One hundred and three patients were treated within 12 hr after onset of acute myocardial infarction (AMI) with primary angioplasty and SES implantation. Those patients were compared to 504 patients treated with bare metal stents (BMSs). Angiographic success (TIMI flow grade 3 and residual stenosis < 50%) was completed in 98% of patients with SESs and no subacute stent thrombosis was reported. In‐hospital outcomes were similar in the SES and BMS groups. At 6 months, major cardiac events were less frequent in the SES group than in the BMS group (9% vs. 24%, respectively; P < 0.001), driven by a lesser need for repeat revascularization with SESs (1% vs. 10.3% with BMSs; P = 0.014). Mortality at 6 months was 7% with SESs and 11% with BMSs ( P = 0.14). SESs are safe and effective for the treatment of AMI by primary angioplasty. As compared to BMSs, SESs improve long‐term outcome after AMI, mainly by reducing the need for repeat revascularization. © 2005 Wiley‐Liss, Inc.